Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCALATE-PPH: Ambrisentan and Tadalafil in Portopulmonary Hypertension
NCT03309592Phase 4Withdrawn
- Sponsor
- Ochsner Clinic Foundation
- Start
- Oct 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ambrisentan, tadalafil in portopulmonary hypertension (POPH), sponsored by Ochsner Clinic Foundation. Planned start Oct 2017; status: withdrawn.
02
Drugs
ambrisentantadalafil
03
Conditions
portopulmonary hypertension (POPH)
Beyond the preview
Go deeper on NCT03309592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03309592.